Gary:
Any insight on LYNX?
5.4 million shares os, market cap is just under $30 million.
biz.yahoo.com
HAYWARD, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Lynx Therapeutics, Inc. (Nasdaq: LYNX - News) today reported operating income of $2.4 million for the quarter ended September 30, 2003, as compared to an operating loss of $2.1 million for the same period in 2002. Lynx's net income was $1.8 million, or $0.38 per diluted share, for the quarter ended September 30, 2003, as compared to a net loss of $3.3 million, or $(0.80) per share, for the 2002 period.
"Our operating performance in the third quarter of 2003 reflects higher genomics revenues and continued aggressive management of our expenses," said Kevin P. Corcoran, Lynx's President and Chief Executive Officer. "The increase in our third quarter 2003 revenues to $8.3 million was due primarily to revenue recognized under our collaboration with Takara Bio, including the sale to them of three MPSS(TM) instruments. We continue to focus on building revenues through increasing the number of Massively Parallel Signature Sequencing, or MPSS(TM), analyses we perform for our customers."
Mr. Corcoran continued, "We are pleased by the recent announcements of new multi-million dollar genomics discovery services agreements with DuPont, which builds on the successes achieved under our present 5-year relationship initiated with them in 1998, and with the University of Delaware to characterize gene expression patterns in the crop plant rice."
biz.yahoo.com
Press Release Source: IBM
IBM, Lynx Therapeutics and the Institute for Systems Biology Announce Study in Systems Biology
Thursday June 5, 2003 8:00 am ET
SOMERS, NY, HAYWARD, CA, and SEATTLE, WA--(MARKET WIRE)--Jun 5, 2003 -- IBM, Lynx Therapeutics, Inc. (NasdaqNM:LYNX - News), and the Institute for Systems Biology (ISB) today announced a collaboration to study how cells of the human immune system respond to infectious diseases.
As part of the agreement, Lynx's Massively Parallel Signature Sequencing, or MPSS™ technology, will be used to generate comprehensive gene expression profiles of human immune system cells provided by the ISB for the study of inflammatory response to microbial infection. IBM will provide middleware for managing, integrating and analyzing the substantial volume of data from this systems biology project.
...
Systems biology involves the analysis of all components of a biological system, which includes an in-depth analysis of how genes are expressed and their complex interactions within a cell, tissue, organ or whole organism. MPSS™ technology is considered an ideal tool for systems biology applications because of its inherent capacity to quantitatively analyze virtually all genes in a sample, including those that are expressed at very low levels.
I always like press releases about microcaps when they are issued by huge partners. |
